Decitabine

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses how advances in the understanding of prognostic biomarkers may help guide the treatment of AML.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses strategies for preventing relapse in patients with AML.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses the biggest challenges in AML care today.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses emerging and experimental therapies being researched for AML.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses the latest advancements in treatment options for acute myeloid leukemia.

SAN DIEGO — Akriti Jain, MD, highlights presentations from ASH Annual Meeting and Exposition focused on triplet combination therapy for patients with acute myeloid leukemia.

Older, fit patients with acute myeloid leukemia who received decitabine had transplant and survival rates comparable to those treated with induction chemotherapy but with fewer toxicities, according to results of a randomized phase 3 study.

In patients with relapsed or refractory or secondary acute myeloid leukemia/myelodysplastic syndromes, decitabine plus ipilimumab had an expected adverse event profile and showed encouraging clinical activity, according to an ongoing phase 1 study.

Recombinant human granulocyte colony-stimulating factor combined with minimal-dose decitabine appeared to reduce relapse incidence after allogeneic transplant among patients with high-risk acute myeloid leukemia, study results showed.

Older patients with myelodysplastic syndrome appeared more likely to receive persistent treatment with hypomethylating agents under the care of more experienced providers of the agents, according to results of a population-based analysis published in Leukemia & Lymphoma.